MARTHA study: MRI-guided, adaptive radiotherapy for head and neck tumors to reduce xerostomia

Radiotherapy is the most important treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). In recent decades, much progress has been made in terms of tumor control and patient survival. However, treatment-related toxicity remains a critical problem, leading to reduced quality of life and permanent impairment for many survivors.

Aim of the study

With this study, we want to investigate whether the use of the new, approved MRIdian® radiation device, which allows integrated MRI (magnetic resonance imaging) imaging during each radiation treatment, precise positioning, as well as simple and regular plan adaptation during the entire therapy series, can reduce the rate of side effects and especially radiation-induced dry mouth (xerostomia) compared to published data.

Who can take part?

Patients with tumors in the head and neck area such as mouth, throat or larynx cancer

Procedure

The study will run for a total of 26 months in parallel with the therapy and follow-up care/controls. The therapy lasts about 7 weeks, as it does outside of the study, after which 3-monthly follow-up appointments are scheduled for a total of 2 years. The following non-invasive study-related examinations are carried out:

1. Salivary flow measurements before the start of radiotherapy (1 day to 4 weeks), and as part of follow-up care after 6, 12 and 24 months.
2. Questionnaire/recording of side effects weekly during therapy and every 3 months as part of follow-up care for up to 24 months

Compensation

None

Original study name

MRI-guided adaptive radiotherapy to reduce xerostomia in head and neck cancer including longitudinal evaluation of the patient's immune profile under radiotherapy

BASEC number

2019-00993

Financial support from

University of Zurich